Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Parkinson's Disease Psychosis Clear all
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin tartrate (ACP-103), Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Gilbert, Arizona • Phoenix, Arizona • Berkeley, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced May 22, 2026, 12:06 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Parkinson Disease Psychosis
Interventions
AGB101
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced May 22, 2026, 12:06 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Dementia-related Psychosis
Interventions
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced May 22, 2026, 12:06 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Parkinson's Disease
Interventions
cannabidiol
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced May 22, 2026, 12:06 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Hallucinations, Psychoses, Parkinson's Disease
Interventions
ACP-103
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
0 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
13
States / cities
Fountain Valley, California • Sunnyvale, California • Danbury, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2005 · Synced May 22, 2026, 12:06 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Parkinson Disease Psychosis
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Scottsdale, Arizona • Fullerton, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced May 22, 2026, 12:06 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Parkinson's Disease
Interventions
EMD 128130, IV Levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 22, 2026, 12:06 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Parkinson's Disease, Psychotic Disorders
Interventions
Melperone HCl, Placebo
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
10
States / cities
Tucson, Arizona • Bradenton, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced May 22, 2026, 12:06 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Parkinson Disease, Parkinson Disease Psychosis, Hallucinations, Delusion
Interventions
Observation of minor phenomena
Other
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced May 22, 2026, 12:06 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin tartrate (ACP-103)
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
La Habra, California • Laguna Hills, California • Reseda, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced May 22, 2026, 12:06 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Parkinson Disease Psychosis
Interventions
Iloperidone
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced May 22, 2026, 12:06 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Parkinson Disease Psychosis
Interventions
Real-world, non-interventional
Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
69
States / cities
Cullman, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced May 22, 2026, 12:06 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
pimavanserin tartrate (ACP-103)
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Danbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced May 22, 2026, 12:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced May 22, 2026, 12:06 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
24
States / cities
Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced May 22, 2026, 12:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Healthy, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 22, 2026, 12:06 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Parkinson Disease
Interventions
Cannabidiol, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced May 22, 2026, 12:06 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
pimavanserin tartrate, placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
62
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced May 22, 2026, 12:06 AM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Parkinson's Disease, Psychoses
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced May 22, 2026, 12:06 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Parkinson Disease Psychosis
Interventions
SEP-363856, Placebo capsule
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 105 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
24
States / cities
Fresno, California • Los Angeles, California • Riverside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced May 22, 2026, 12:06 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin tartrate (ACP-103)
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
83
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced May 22, 2026, 12:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Schizophrenia, Parkinson's Disease
Interventions
18F-Fluoro-L-dopa, O-15 Water
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 90 Years
Enrollment
502 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 22, 2026, 12:06 AM EDT
Recruiting Phase 4 Interventional
View directory record Official record
Conditions
Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced May 22, 2026, 12:06 AM EDT